Press Releases

CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research

Apr 18, 2017

Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Celleron Therapeutics announces completion of a new funding round with international investors

Jan 31, 2017

Oxford 31st January 2017; Celleron Therapeutics Limited, the UK-based precision cancer medicines company, focussed on clinical trials of novel small

Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients

Dec 1, 2015

Oxford, UK, 1st December 2015; Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced that

« Previous
1
2
3